INTRODUCTION

Myasthenia gravis (MG) is a chronic autoimmune disorder characterised by the production of autoantibodies directed against components of the postsynaptic neuromuscular junction, most commonly the acetylcholine receptor (AChR) [1,2]. The hallmark clinical feature is fluctuating muscle weakness that worsens with sustained activity and improves at rest. In its most severe form, MG may precipitate a myasthenic crisis, defined as acute respiratory failure secondary to weakness of the respiratory and bulbar muscles, requiring mechanical ventilatory support [3,4]. Myasthenic crisis occurs in 15–20% of patients with MG during the course of their disease and remains a neurologic emergency with significant morbidity and mortality if not managed promptly in an intensive care setting [5,6].

The cornerstone of acute immunomodulatory therapy for myasthenic crisis consists of either therapeutic plasma exchange (TPE) or intravenous immunoglobulin (IVIG) therapy. Multiple randomised trials and meta-analyses have demonstrated comparable efficacy between these two modalities in achieving rapid clinical improvement and reducing the duration of mechanical ventilation [7,8]. However, the choice between TPE and IVIG must be individualised based on patient-specific factors, including haemodynamic stability, vascular access feasibility, coagulation profile, cardiac comorbidities, and institutional resources [9,10].

IVIG exerts its therapeutic effects through multiple mechanisms, including the neutralisation of pathogenic autoantibodies, inhibition of complement activation, modulation of Fc-receptor function, suppression of proinflammatory cytokines, and downregulation of autoreactive T- and B-cell responses [11,12]. In contrast to TPE, IVIG administration is noninvasive, does not require central venous catheterisation or specialised apheresis equipment, and is associated with a more stable haemodynamic profile [13]. These characteristics make IVIG particularly advantageous in patients with coagulopathy, bradyarrhythmia, advanced age, or limited vascular access, conditions that significantly increase the risk of TPE-related complications such as hypotension, arrhythmia, bleeding, thrombosis, and catheter-associated infection [14,15].This case report describes the successful intensive care management of a patient presenting with myasthenic crisis complicated by a hypercoagulable state and bradyarrhythmia, highlighting the clinical rationale for preferring IVIG over TPE and underscoring the importance of tailored immunomodulatory therapy in critically ill patients with complex comorbidities.

CASE DESCRIPTION

A 39-year-old woman (body weight 50 kg, height 156 cm) with a two-year history of acetylcholine receptor antibody-positive myasthenia gravis, previously treated with azathioprine 50 mg daily, presented to the emergency department of Dr. Hasan Sadikin Central Hospital with progressive symptoms. Seven days prior to admission, she developed difficulty walking, dysphagia requiring a soft/liquid diet, and bilateral ptosis. Three days before admission, profound limb weakness precluded lifting of the arms or legs, and two days prior, she became excessively somnolent. Over the final 24 h, the dyspnoea markedly worsened.

On arrival, the patient was fully conscious but in respiratory distress. Vital signs revealed blood pressure of 117/87 mmHg, heart rate of 56 beats/min (sinus bradycardia), respiratory rate of 40–46 breaths/min, and SpO2 of 90–93% on a non-rebreather mask at 15 L/min. Due to impending respiratory failure, she was intubated in the emergency department and transferred to the general intensive care unit (GICU) for further management. Initial ICU assessment showed Glasgow Coma Scale E3M5VETT (intubated), blood pressure 122/82 mmHg, heart rate 64 beats/min, and stable oxygenation on pressure-synchronised intermittent mandatory ventilation (P-SIMV) with pressure control of 10 cmH₂O, pressure support of 10 cmH₂O, PEEP of 5 cmH₂O, and FiO₂ of 60%. The pertinent laboratory findings on admission are summarised in Table 1.

Table 1. Key laboratory results on ICU admission

The patient was diagnosed with a myasthenic crisis complicated by sinus bradyarrhythmia, a hypercoagulable state (elevated D-dimer with prolonged prothrombin time, INR, and activated partial thromboplastin time), severe hyponatraemia, and hypokalaemia. These comorbidities, together with haemodynamic considerations, guided the subsequent therapeutic strategies.

Table 2. Laboratory findings on intensive care unit admission

DISCUSSION

Myasthenia gravis (MG) is an antibody-mediated autoimmune disorder targeting the postsynaptic neuromuscular junction, with acetylcholine receptor (AChR) antibodies present in approximately 85% of generalised cases, whereas MuSK and LRP4 antibodies account for most of the remainder. A small seronegative subgroup exists, despite the use of sensitive assays [1,2]. The clinical hallmark is fatigable muscle weakness, often beginning with ocular symptoms and progressing to generalised disease in most patients. Myasthenic crisis, defined as acute exacerbation causing respiratory failure necessitating mechanical ventilation, complicates 15–20% of cases and remains associated with substantial morbidity if not aggressively managed in an intensive care setting [3,4].

Rapid immunomodulatory therapy is the cornerstone of the treatment. High-quality evidence from randomised controlled trials and systematic reviews confirms that intravenous immunoglobulin (IVIG) and therapeutic plasma exchange (TPE) are equally efficacious in achieving early clinical improvement, reducing the duration of mechanical ventilation, and shortening the ICU stay [5–7]. However, TPE is limited by its invasive nature, requirement for large-bore central venous access, citrate-induced hypocalcaemia, haemodynamic fluctuations, and an increased risk of catheter-related infection or thrombosis [8,9]. These complications are particularly undesirable in patients with coagulopathy, bradyarrhythmia, and limited vascular access.

In the present case, the laboratory findings at admission revealed a hypercoagulable state (D-dimer, 713 ng/mL, with prolonged PT, INR, and aPTT) alongside persistent sinus bradyarrhythmia (heart rate, 56–64 beats/min). These comorbidities render TPE relatively contraindicated because of the unacceptable risks of bleeding, arrhythmia exacerbation, and haemodynamic instability during rapid volume shifts [10,11]. Therefore, IVIG was administered at a standard dose of 0.4 g/kg/day for five consecutive days (total 2 g/kg body weight). This regimen exerts multiple immunomodulatory effects, including neutralisation of pathogenic autoantibodies, Fc-receptor blockade, complement inhibition, and cytokine modulation, without the procedural hazards of TPE [12,13]. The patient demonstrated marked clinical improvement within days, with progressive recovery of respiratory and bulbar muscle strength, successful extubation on day 8, and transfer to the high-care unit on day 9—outcomes fully consistent with large multicentre registries and recent meta-analyses of IVIG-treated myasthenic crisis [14-16].

Concomitant intensive care management adhered to the contemporary guidelines. Severe hyponatraemia (122.6 mmol/L) and hypokalaemia (2.0 mmol/L) were cautiously corrected to prevent central pontine myelinolysis. Early enteral nutrition was initiated within 48 h after confirmation of high nutritional risk by NRS-2002 and modified NUTRIC scores, targeting 25–30 kcal/kg/day and 1.6–2.0 g/kg/day protein according to ASPEN/SCCM recommendations [17]. Pain and sedation were managed using validated behavioural scales (Figure 1).

Figure 1. Pain Assessment (Behavioral Pain Scale)

with an early transition from midazolam to dexmedetomidine and low-dose fentanyl to minimise delirium and ventilator days in accordance with the 2018 PADIS guidelines [18]. Pharmacologic thromboprophylaxis with low-molecular-weight heparin was instituted after formal risk stratification using Padua and IMPROVE scores (Figure 2) [19,20], and standard measures for stress-ulcer and aspiration prevention were applied.

Figure 2. Recommendations for Thromboprophylaxis

This case underscores the critical importance of individualised immunomodulatory treatment in myasthenic crises. When complicated by hypercoagulability and bradyarrhythmia, IVIG is a safer, equally effective, and logistically superior alternative to plasma exchange [21,22]. When integrated within a comprehensive, evidence-based critical care protocol, IVIG reliably produces rapid neurological recovery and favourable short-term outcomes in high-risk populations.

CONCLUSION

This case confirms that intravenous immunoglobulin (IVIG) is a safe and highly effective first-line therapy for myasthenic crisis complicated by hypercoagulability and bradyarrhythmia, in which plasma exchange is relatively contraindicated. Administered at 2 g/kg over five days within a comprehensive, multidisciplinary ICU protocol, IVIG achieved rapid clinical improvement, successful extubation on day 8, and excellent outcomes without complications. IVIG should be prioritised for similar high-risk presentations.

DECLARATIONS

None

CONSENT FOR PUBLICATION

The Authors agree to be published in the Journal of Society Medicine.

FUNDING

None

COMPETING INTERESTS

The authors declare no conflicts of interest in this case report.

AUTHORS’ CONTRIBUTIONS

All authors made substantial contributions to the case report. APP was responsible for patient management, data collection, and initial drafting of the manuscript. All authors reviewed and approved the final version of the manuscript, ensuring its accuracy and integrity, and are accountable for all aspects of the work.

ACKNOWLEDGMENTS

None

REFERENCE

1. Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren JJGM. Myasthenia gravis. Nat Rev Dis Primers. 2019;5(1):30.

2. Wendell LC, Levine JM. Myasthenic crisis. Neurohospitalist. 2011;1(1):16-22.

3. Qureshi AI, Choudhry MA, Akbar MS, Mohammad Y, Chua HC, Yahia AM, et al. Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis. Neurology. 1999;52(3):629.

4. Ferrero B, Durelli L. High-dose intravenous immunoglobulin G treatment of myasthenia gravis. Neurol Sci. 2002;23(Suppl 1):S9-S24.

5. Yeh JH, Chen HJ, Chen YK, Chiu HC, Kao CH. Increased risk of osteoporosis in patients with myasthenia gravis. Neurology. 2014;83(12):1075-9.

6. Pavlekovics M, Engh MA, Lugosi K, Szabo L, Hegyi P, Terebessy T, et al. Plasma exchange versus intravenous immunoglobulin in worsening myasthenia gravis: a systematic review and meta-analysis with special attention to faster relapse control. Biomedicines. 2023;11(12):3180.

7. Nishikawa N, Nagai M, Tsujii T, Kyaw WT, Tanabe N, Iwaki H, et al. Treatment of myasthenia gravis in patients with elderly onset at advanced age. Jpn Clin Med. 2015;6:1-7.

8. Szczeklik W, Wawrzycka K, Włudarczyk A, Sega A, Nowak I, Seczyńska B, et al. Complications in patients treated with plasmapheresis in the intensive care unit. Anaesthesiol Intensive Ther. 2013;45(1):7-13.

9. Ortiz-Salas P, Velez-Van-Meerbeke A, Galvis-Gomez CA, Rodriguez JH. Human immunoglobulin versus plasmapheresis in Guillain-Barre syndrome and myasthenia gravis: a meta-analysis. J Clin Neuromuscul Dis. 2016;18(1):1-11.

10. McClave SA, Taylor BE, Martindale RG, Warren MM, Johnson DR, Braunschweig C, et al. Guidelines for the provision and assessment of nutrition support therapy in the adult critically ill patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.). JPEN J Parenter Enteral Nutr. 2016;40(2):159-211.

11. Kondrup J, Rasmussen HH, Hamberg O, Stanga Z; Ad Hoc ESPEN Working Group. Nutritional risk screening (NRS 2002): a new method based on an analysis of controlled clinical trials. Clin Nutr. 2003;22(3):321-36.

12. Heyland DK, Dhaliwal R, Jiang X, Day AG. Identifying critically ill patients who benefit the most from nutrition therapy: the development and initial validation of a novel risk assessment tool. Crit Care. 2011;15(6):R268.

13. de Letter MA, Schmitz PI, Visser LH, Verheul FA, Schellens RL, Op de Coul DA, et al. Risk factors for the development of polyneuropathy and myopathy in critically ill patients. Crit Care Med. 2001;29(12):2281-6.

14. Gélinas C, Fillion L, Puntillo KA, Viens C, Fortier M. Validation of the critical-care pain observation tool in adult patients. Am J Crit Care. 2006;15(4):420-7.

15. Seo Y, Lee HJ, Ha EJ, Ha TS. 2021 KSCCM clinical practice guidelines for pain, agitation, delirium, immobility, and sleep disturbance in the intensive care unit. Acute Crit Care. 2022;37(1):1-25.

16. Gélinas C, Fillion L, Puntillo KA, Viens C, Fortier M. Validation of the critical-care pain observation tool in adult patients. Am J Crit Care. 2006;15(4):420-7. (duplicate of ref. 14)

17. Morales Castro D, Dresser L, Granton J, Fan E. Pharmacokinetic alterations associated with critical illness. Clin Pharmacokinet. 2023;62(2):209-20.

18. Davidson JE, Winkelman C, Gélinas C, Dermenchyan A. Pain, agitation, and delirium guidelines: nurses’ involvement in development and implementation. Crit Care Nurse. 2015;35(3):17-31.

19. Kahn SR, Lim W, Dunn AS, Cushman M, Dentali F, Akl EA, et al. Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e195S-e226S.

20. Barbar S, Noventa F, Rossetto V, Ferrari A, Brandolin B, Perlati M, et al. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. J Thromb Haemost. 2010;8(11):2450-7.

21. Rosenberg D, Eichorn A, Alarcon M, McCullagh L, McGinn T, Spyropoulos AC. External validation of the risk assessment model of the International Medical Prevention Registry on Venous Thromboembolism (IMPROVE) for medical patients in a tertiary health system. J Am Heart Assoc. 2014;3(6):e001152.

22. Skeik N, Westergard E. Recommendations for VTE prophylaxis in medically ill patients. Ann Vasc Dis. 2020;13(1):38-43.